Evidence map›Paper›PMID 35280863›Full record

ArticleFrontiers in medicine2022

Progression-Free Survival Prediction in Small Cell Lung Cancer Based on Radiomics Analysis of Contrast-Enhanced CT.

Ningxin Chen, Ruikun Li, Mengmeng Jiang, Yixian Guo, Jiejun Chen, Dazhen Sun, Lisheng Wang, Xiuzhong Yao

Abstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Baseline ¹BMC cancer · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Predicting response and survival to first-line treatment with baseline [Therapeutic advances in medical oncology · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ningxin ChenDepartment of Radiology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Ruikun LiDepartment of Automation, Shanghai Jiao Tong University, Shanghai, China.
Mengmeng JiangDepartment of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital of Fudan University, Shanghai, China.
Yixian GuoDepartment of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital of Fudan University, Shanghai, China.
Jiejun ChenDepartment of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital of Fudan University, Shanghai, China.
Dazhen SunDepartment of Automation, Shanghai Jiao Tong University, Shanghai, China.
Lisheng WangDepartment of Automation, Shanghai Jiao Tong University, Shanghai, China.
Xiuzhong YaoDepartment of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital of Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purposes and Objectives: The aim of this study was to predict the progression-free survival (PFS) in patients with small cell lung cancer (SCLC) by radiomic signature from the contrast-enhanced computed tomography (CT). Methods: A total of 186 cases with pathological confirmed small cell lung cancer were retrospectively assembled. First, 1,218 radiomic features were automatically extracted from tumor region of interests (ROIs) on the lung window and mediastinal window, respectively. Then, the prognostic and robust features were selected by machine learning methods, such as (1) univariate analysis based on a Cox proportional hazard (CPH) model, (2) redundancy removing using the variance inflation factor (VIF), and (3) multivariate importance analysis based on random survival forests (RSF). Finally, PFS predictive models were established based on RSF, and their performances were evaluated using the concordance index (C-index) and the cumulative/dynamic area under the curve (C/D AUC). Results: In total, 11 radiomic features (6 for mediastinal window and 5 for lung window) were finally selected, and the predictive model constructed from them achieved a C-index of 0.7531 and a mean C/D AUC of 0.8487 on the independent test set, better than the predictions by single clinical features (C-index = 0.6026, mean C/D AUC = 0.6312), and single radiomic features computed in lung window (C-index = 0.6951, mean C/D AUC = 0.7836) or mediastinal window (C-index = 0.7192, mean C/D AUC = 0.7964). Conclusion: The radiomic features computed from tumor ROIs on both lung window and mediastinal window can predict the PFS for patients with SCLC by a high accuracy, which could be used as a useful tool to support the personalized clinical decision for the diagnosis and patient management of patients with SCLC.

Indexed as

contrast-enhanced CTmediastinal windowprogression-free survival (PFS)radiomics analysissmall cell lung cancer (SCLC)

Identifiers

PMID35280863
PMCPMC8911879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.